CAS: 75847-73-3; Enalapril

该化合物是一种主要用于治疗高血压和心脏衰竭的抗动脉素抑制剂,是一种在身体中转化成活性形式的抗药剂,蛋白质为C20H28N2O5,其化学配方是C20-H28 N2O5.,其特点是一种致癌基体,一个矿物质组和一个苯基环,有助于其药理活动.Enalapril通过抑制ACE酶而进行工作,该酶主要用于减少Achotensin II(一种强效血管抑制剂)的生产,导致血管扩张和血压下降.该物质通常通过口服方式施用,并且以相对长的半衰期为人所知,允许一次使用.常见的副作用包括咳嗽,高的钾含量,以及在罕见的情况下,安吉亚德马.Enalapril通常与其他抗体剂结合处方,以提高治疗功效.与任何药物一样,它对于监测病人的潜在不利影响和与其他药物的相互作用至关重要.

结构式图片

欧盟法规

C&L通报REACH预注册

上下游产品

2-oxo-4-phenylbutanoic acid ethyl ester L-alanyl-L-proline -L-alanyl-L-proline BenzylesterN-(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl-L-alanyl-L-proline Benzylester -L-alanyl>-L-proline tert butyl esterN--L-alanyl-L-proline tert butyl esterenalaprilate Amprace (S)-2-((3S,8aS)-3-Methyl-1,4-dioxo-hexahydro-pyrrolo[1,2-a]pyrazin-2-yl)-4-phenyl-butyric acid ethyl ester enalaprilic acid

合成工艺路线路线简述

  • 合成目标产物 Enalapril 主要起始原料 Ethyl 2-Oxo-4-Phenylbutyrate And L-Alanyl-L-Proline
  • (文献来源)合成步骤主要原料 Ethyl 2-Oxo-4-Phenylbutyrate 和 L-Alanyl-L-Proline
N-<(1S)-1-(Ethoxycarbonyl)-3-Phenylpropyl>-L-Alanyl-L-Proline Benzylester置于palladium On Activated Charcoal 氢气体系中,用 乙醇 作为反应溶剂,化学反应 2.0H,反应生成 依那普利
参考文献:Studies On Angiotensin Converting Enzyme Inhibitors. V. The Diastereoselective Synthesis Of 2-Oxoimidazolidine Derivatives.
标题:Studies On Angiotensin Converting Enzyme Inhibitors. V. The Diastereoselective Synthesis Of 2-Oxoimidazolidine Derivatives.
摘要:建立了一种具有二面体选择性的imidapril(1)合成方法,该药物正在进行临床研究,作为一种基于其血管紧张素转化酶(ace)抑制活性的抗高血压药物.将(2S)-2-Amino-4-Phenylbutyric Acid Ester(12)与3-((2R)-2-甲基或甲苯磺酰氧丙酰)-2-氧代咪唑烷衍生物(11)通过sn2方式进行n-烷基化,选择性地反应生成叔丁基(4S)-3-[(2S)-2-[n-[(1S)-1-乙氧基碳酰基)-3-苯基丙基]氨基]丙酰]-1-甲基-2-氧代咪唑烷-4-羧酸酯(13),该化合物是1的前体.作为替代,合成了苄基(2S)-2-[n-(1S)-1-(乙氧基碳酰基)-3-苯基丙基]氨基]丙酸酯(15),这是13的关键构件.该程序也应用于enalapril的合成.
DOI:10.1248/cpb.39.1374

海关参考信息

专利信息


专利号:US-9353057-B2
优先权日:2003-12-30
标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
发明人:GALLOP MARK A; DAI XUEDONG; SCHEUERMAN RANDALL A; RAILLARD STEPHEN P; MANTHATI SURESH K; YAO FENMEI; PHAN THU; LUDWIKOW MARIA; PENG GE; BHAT SEEMA
权利人:XENOPORT INC
摘要:Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

专利号:US-7169589-B2
优先权日:2000-07-28
标题 :Silicatein-mediated synthesis of amorphous silicates and siloxanes and use thereof
发明人:MUELLER WERNER E G; SCHROEDER HEINZ C; LORENZ BERND; KRASKO ANATOLI
权利人:MUELLER WERNER E G; SCHROEDER HEINZ C; LORENZ BERND; KRASKO ANATOLI
摘要:Silicatein is an enzyme of silicate-forming organisms used for the synthesis of their silicate scaffold. The present invention relates to the use of highly-expressed and highly active recombinant silicatein, silicatein isolated from natural sources after gene induction as well as silicatein-fusion proteins for the synthesis of amorphous silicon dioxide (silicic acids and silicates), siloxanes as well as modification of these compounds and their technical use.

专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

专利号:US-10973847-B2
优先权日:2017-06-30
标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof
发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.

专利号:US-10005720-B2
优先权日:2013-04-05
标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

专利号:US-7094920-B2
优先权日:2001-05-21
标 题 :Stereoselective synthesis of 2-hydroxy-4-phenylbutyric acid esters
发明人:TIKARE RAVEENDRA KHANDURAO
权利人:FERMENTA BIOTECH LTD
摘要:A process is described for the stereospecific preparation of an ester of formula (I): wherein * signifies the (R) stereoisomer; R 1 is selected from C 1-6 alkyl, preferably ethyl; and R 2 is hydrogen, a protecting group or a leaving group which process comprises reaction of a nitrile of formula (II): wherein * signifies the (R) stereoisonomer; and Ph is the phenyl group C 6 H 5 with a solution of an inorganic acid in an alcohol and optional conversion of the compound of formula (I) wherein R 2 is H so prepared to any other desired compound of formula (I) by standard methods in the art. The compounds of formula (I) are chiral esters, useful as intermediates in the synthesis of the family of acetylcholine esterase (ACE) inhibitors known as “prilsâ€?, such as lisinopril, cilazapril, enalapril, benazepril, ramipril, delapril, enalaprilat, imidapril, spirapril, trandolapril and others.n n*n nPh-CH 2 —CH 2 —CH(OR 2 )—COOR 1   (I)n n*n nPh-CH 2 —CH 2 —CH(H)—CN  (II)
浙江昌明化学制品有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.changming.com.cn
电话: 86-576-3661858 3669333👤
📞浙江昌明化学制品有限公司 ⚠️参考联系方式

销售电话:86-576-3661858 3669333
邮箱:sales@changming.com.cn
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
台州市震旦药物技术有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.orpharma.com
电话: 0086-576-88204560👤
📞台州市震旦药物技术有限公司 ⚠️参考联系方式

销售电话:0086-576-88204560
邮箱:Orpharma@yahoo.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Moffett BS, DiSanto AR, Espinosa O, Hou J, Colabuono P. Bioequivalence of enalapril oral solution for treatment of pediatric hypertension and enalapril tablets. Clin Pharmacol Drug Dev. 2014 Nov;3(6):493-8. doi: 10.1002/cpdd.129. Epub 2014 Jun 27. doi: 10.1016/j.rvsc.2014.06.006. Epub 2014 Jun 12. doi: 10.1111/jphp.12471. Epub 2015 Aug 10. doi: 10.1111/bcp.12667. Epub 2015 Jun 11.
5: Maldonado J, Pereira T, Tavares A. Efficacy and safety of a lercanidipine/enalapril fixed-dose combination in hypertensive patients in Portugal. Drugs R D. 2014 Jun;14(2):147-54. doi: 10.1007/s40268-014-0046-8.
6: CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 4;316(23):1429-35. doi: 10.1016/j.rvsc.2014.01.006. Epub 2014 Feb 3. German. doi: 10.1002/bmc.3201. Epub 2014 May 2. Epub 2016 Jul 19. Erratum in: N Engl J Med 1992 Dec 10;327(24):1768. doi: 10.1002/bmc.1716. Epub 2011 Sep 23. eCollection 2016. Review.

合成参考文献


参考文献:10.2165/11531660-000000000-00000
摘要:Merli M, Bragazzi MC, Giubilo F, Callea F, Attili AF, Alvaro D. Atorvastatin-induced prolonged cholestasis with bile duct damage. Clin Drug Investig. 2010;30(3):205–9. doi: 10.2165/11531660-000000000-00000.
参考文献:10.1007/s00467-009-1434-0
摘要:Caletti MG, Balestracci A, Roy AH. Levels of urinary transforming growth factor beta-1 in children with D+ hemolytic uremic syndrome. Pediatr Nephrol. 2010 Jun;25(6):1177–80. doi: 10.1007/s00467-009-1434-0.
参考文献:10.4061/2011/132405
摘要:Tedla FM, Brar A, Browne R, Brown C. Hypertension in Chronic Kidney Disease: Navigating the Evidence. International Journal of Hypertension. 2011;2011():1–9. doi: 10.4061/2011/132405.
参考文献:10.4061/2011/346985
摘要:Essick EE, Sam F. Cardiac Hypertrophy and Fibrosis in the Metabolic Syndrome: A Role for Aldosterone and the Mineralocorticoid Receptor. International Journal of Hypertension. 2011;2011():1–12. doi: 10.4061/2011/346985.
参考文献:10.4061/2011/417594
摘要:Demede M, Pandey A, Innasimuthu L, Jean-Louis G, McFarlane SI, Ogedegbe G. Management of Hypertension in High-Risk Ethnic Minority with Heart Failure. International Journal of Hypertension. 2011;2011():1–8. doi: 10.4061/2011/417594.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知